CN116531433A - Liquid wound healing agent of garden burnet and application thereof - Google Patents
Liquid wound healing agent of garden burnet and application thereof Download PDFInfo
- Publication number
- CN116531433A CN116531433A CN202310515553.XA CN202310515553A CN116531433A CN 116531433 A CN116531433 A CN 116531433A CN 202310515553 A CN202310515553 A CN 202310515553A CN 116531433 A CN116531433 A CN 116531433A
- Authority
- CN
- China
- Prior art keywords
- parts
- oil
- sanguisorba
- healing agent
- sanguisorba officinalis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000008282 Sanguisorba officinalis Nutrition 0.000 title claims abstract description 66
- 244000173853 Sanguisorba officinalis Species 0.000 title claims abstract description 63
- 239000007788 liquid Substances 0.000 title claims abstract description 27
- 235000008291 Poterium sanguisorba Nutrition 0.000 title claims abstract description 23
- 239000003357 wound healing promoting agent Substances 0.000 title claims abstract description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000003921 oil Substances 0.000 claims abstract description 31
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 27
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 27
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 22
- 206010052428 Wound Diseases 0.000 claims abstract description 21
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 16
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003462 dyclonine hydrochloride Drugs 0.000 claims abstract description 15
- KNZADIMHVBBPOA-UHFFFAOYSA-N dyclonine hydrochloride Chemical compound [Cl-].C1=CC(OCCCC)=CC=C1C(=O)CC[NH+]1CCCCC1 KNZADIMHVBBPOA-UHFFFAOYSA-N 0.000 claims abstract description 15
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 14
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 14
- 235000003434 Sesamum indicum Nutrition 0.000 claims abstract description 14
- 229960000846 camphor Drugs 0.000 claims abstract description 14
- 229930008380 camphor Natural products 0.000 claims abstract description 14
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims abstract description 14
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims abstract description 13
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 13
- 244000242564 Osmanthus fragrans Species 0.000 claims abstract description 13
- 235000019083 Osmanthus fragrans Nutrition 0.000 claims abstract description 13
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims abstract description 13
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims abstract description 13
- 239000000341 volatile oil Substances 0.000 claims abstract description 13
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 12
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000013003 healing agent Substances 0.000 claims abstract description 7
- 241000581682 Sanguisorba Species 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 241000207961 Sesamum Species 0.000 claims description 12
- 230000001737 promoting effect Effects 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 14
- 208000002193 Pain Diseases 0.000 abstract description 10
- 230000036407 pain Effects 0.000 abstract description 10
- 230000035876 healing Effects 0.000 abstract description 5
- 244000000231 Sesamum indicum Species 0.000 abstract description 2
- 230000009471 action Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 235000019198 oils Nutrition 0.000 description 21
- 208000032843 Hemorrhage Diseases 0.000 description 16
- 208000034158 bleeding Diseases 0.000 description 16
- 238000001816 cooling Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000000944 linseed oil Substances 0.000 description 3
- 235000021388 linseed oil Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 240000000950 Hippophae rhamnoides Species 0.000 description 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000019498 Walnut oil Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000010460 hemp oil Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000008170 walnut oil Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000157511 Oldenlandia Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 description 1
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000009453 Thyroid Nodule Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 244000058281 Ulmus pumila Species 0.000 description 1
- 235000001547 Ulmus pumila Nutrition 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a liquid wound healing agent of sanguisorba officinalis and application thereof, and belongs to the technical field of medicines. The liquid wound-promoting and healing agent for sanguisorba officinalis consists of the following components in parts by weight: 40-80 parts of nitrocellulose, 30-40 parts of sesame blend oil, 15-25 parts of benzyl alcohol, 1-3 parts of tocopheryl acetate, 2-4 parts of camphor, 1-3 parts of benzalkonium chloride, 18-21 parts of isopropyl palmitate, 1-2 parts of osmanthus fragrans oil, 4-6 parts of orange essential oil, 20-40 parts of sanguisorba extract, 8-12 parts of dyclonine hydrochloride, 380-420 parts of isopropanol, 200-240 parts of ethyl acetate and 170-190 parts of butyl acetate. The liquid wound healing agent of the garden burnet root is added with some medicines for relieving pain and stopping bleeding, so that the healing of wounds is quickened under the action of the medicines and in a moist environment, and the pain of a patient suffering from the wounds is reduced.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a liquid wound healing agent of sanguisorba officinalis and application thereof.
Background
The concept of "wet wound healing" is increasingly widely accepted. In recent years, rapid developments in materials and industry have led to an epoch-making change in wound dressing, and a variety of new dressing have been developed and actively used in clinic. Because in the continuous research process from traditional dressing to novel dressing, medical dressing combines advanced knowledge in many aspects such as biology, physiology, operation, nursing and nutrition, and simultaneously applies various actual demands of patients on dressing such as physics, clinic and the like to dressing material selection and morphological design. The novel scab skin replacement agent has the general characteristics of preventing scab skin formation, preventing adhesion of newly generated granulation tissues and having no pain in replacement; the dissolution of fibrin and necrotic tissues is facilitated, and the replacement times are reduced; creating a low-oxygen environment, promoting capillary angiogenesis, promoting the release of various growth factors and activating the growth factors; relieving pain of wound surface, reducing scar formation, etc.
Disclosure of Invention
The invention aims to provide a liquid wound-promoting and healing agent for sanguisorba officinalis, which comprises the following components in parts by weight: 40-80 parts of nitrocellulose, 30-40 parts of sesame blend oil, 15-25 parts of benzyl alcohol, 1-3 parts of tocopheryl acetate, 2-4 parts of camphor, 1-3 parts of benzalkonium chloride, 18-21 parts of isopropyl palmitate, 1-2 parts of osmanthus fragrans oil, 4-6 parts of orange essential oil, 20-40 parts of sanguisorba extract, 8-12 parts of dyclonine hydrochloride, 380-420 parts of isopropanol, 200-240 parts of ethyl acetate and 170-190 parts of butyl acetate.
Preferably, the garden burnet liquid wound healing agent consists of the following components in parts by weight: 60 parts of nitrocellulose, 35 parts of sesame blend oil, 20 parts of benzyl alcohol, 2 parts of tocopheryl acetate, 3 parts of camphor, 2 parts of benzalkonium chloride, 19.8 parts of isopropyl palmitate, 1.2 parts of osmanthus fragrans oil, 5 parts of orange essential oil, 30 parts of sanguisorba extract, 10 parts of dyclonine hydrochloride, 405 parts of isopropanol, 225 parts of ethyl acetate and 182 parts of butyl acetate.
Preferably, the garden burnet liquid wound healing agent consists of the following components in parts by weight: 80 parts of nitrocellulose, 38 parts of sesame blend oil, 18 parts of benzyl alcohol, 2.5 parts of tocopheryl acetate, 3.5 parts of camphor, 1.5 parts of benzalkonium chloride, 20 parts of isopropyl palmitate, 1.5 parts of osmanthus fragrans oil, 4.5 parts of orange essential oil, 25 parts of garden burnet extract, 10.5 parts of dyclonine hydrochloride, 390 parts of isopropanol, 230 parts of ethyl acetate and 175 parts of butyl acetate.
Preferably, the garden burnet liquid wound healing agent consists of the following components in parts by weight: 40 parts of nitrocellulose, 32 parts of sesame blend oil, 18 parts of benzyl alcohol, 2.8 parts of tocopheryl acetate, 2.5 parts of camphor, 2.5 parts of benzalkonium chloride, 18.9 parts of isopropyl palmitate, 1.8 parts of osmanthus fragrans oil, 5.5 parts of orange essential oil, 35 parts of garden burnet extract, 9 parts of dyclonine hydrochloride, 420 parts of isopropanol, 222 parts of ethyl acetate and 190 parts of butyl acetate.
More preferably, the preparation method of the sanguisorba officinalis extract comprises the following steps: 5500-6500 parts of garden burnet raw material; extracting and drying the raw medicinal liquid: (1) washing the sanguisorba officinalis and soaking the sanguisorba officinalis in water for 12 hours; (2) the sanguisorba officinalis is boiled for 1 hour by 10 times of water; (3) boiling the secondary sanguisorba officinalis with 5 times of water for 1 hour; (4) discarding residues to obtain an extract; (5) spray drying.
The second purpose of the invention is to provide the application of the sanguisorba officinalis liquid wound healing agent in preparing the medicine for promoting the wound healing.
Sanguisorba root, radix Sanguisorbae, bitter in taste, sour, slightly cold in qi, and nontoxic in nature, and also in yin and yang. For metrorrhagia, metrostaxis and menostaxis, it is indicated for infantile malnutrition and fever, dysentery with heat, blood stasis, wind-heat in the intestines and blood stasis, and it is used for treating sore. But for heat but not cold, it is not advisable to cool blood of Yu for people with deficiency cold. For blood heat disease, it is good at cooling blood and promoting the generation of blood. However, blood heat is required to move, and there is a fear of dissipation. Blood cold is congealed again, and there is accumulation of blood stasis. When the sanguisorba is used for cooling blood, heat becomes cool, yin cold is accumulated in intestines and stomach, symptoms of abdominal pain are generated, the blood is not allowed to flow due to metrorrhagia, the sanguisorba is not enough, and the medicine for cooling blood is added, so that the heat is needed to be stopped after death, and the symptoms of the pain are good-!
Compendium, compendium: sanguisorba root, radix Sanguisorbae, with the effect of removing the lower-jiao heat, is indicated for the syndrome of hematochezia and urine. For hemostasis, it is stir-baked to get the upper section, its tip can move blood, but it is not known. Yang Shiying cloud: radix Sanguisorbae and radix Scutellariae can be added for patients with sore and pain, and radix Scutellariae can be added for patients with itching. Materia medica true: sanguisorba root, radix Sanguisorbae, and all books are bitter and cold in nature, can be used to remove heat from the blood in the lower energizer, so that heat is known from the lower part. In addition, it is sinking and astringent, so it can astringe blood without resolving any kind of symptoms such as vomiting, epistaxis, metrorrhagia, diarrhea and the like. According to the above, , it is known that heat is not removed, blood is not sufficient, heat is clear, blood is self-safe, and its nature is mainly converged, so that it can clear and descend and astringe, and the clearing and astringing do not take into consideration its excessive diarrhea, astringency does not take into consideration its or stagnancy, and the powerful antipyretic hemostatics.
Tiger bite from Mei Shi Fang: the sanguisorba root is boiled to drink and is not applied. Or powder, white soup, and three days. It is contraindicated. Materia medica preparation: sanguisorba root, radix Sanguisorbae is used for stopping bleeding and is stir-baked. For promoting blood circulation, taking down and stopping bleeding. So as to astringe blood.
The product has good effect, one of the most important raw materials is the garden burnet, the garden burnet has the effects of cooling blood and stopping bleeding, detoxifying and healing sores, the main components of the garden burnet comprise tannins, saponins, flavones and the like, and the pharmacological activity of the garden burnet has the effects of resisting inflammation, oxidization, allergy, bacteria and viruses, affecting blood systems, affecting biological membranes and the like. The clinical application characteristics of the garden burnet are summarized by collecting the clinical experience and clinical application of ancient medical books and modern doctors, wherein the dosage range of the decoction is 2.9-74 g, and the clinical common dosage is 9-30 g; the common dosage range of the pill and the powder is 3-30 g; the dosage range for external application is 3-60 g. The optimal dosage is selected according to the diseases, symptoms and symptoms, for example, 10-30 g is commonly used when cooling blood and stopping bleeding, removing blood stasis and detoxifying and treating uterine bleeding, thyroid nodule, hyperplasia of mammary glands, hysteromyoma and other gynecological diseases; when the traditional Chinese medicine composition is used for cooling blood, stopping bleeding, detoxifying and healing sores to treat digestive system diseases such as gastric ulcer, ulcerative colitis, constipation and the like, 3-30 g of traditional Chinese medicine composition and 3-20 g of traditional Chinese medicine composition; when the skin diseases such as psoriasis, herpes zoster, burns and scalds and the like are treated by clearing heat and detoxicating and healing sores, 10-30 g of the skin diseases are commonly used, and 10-60 g of the skin diseases are commonly used for external use; when the Chinese medicinal composition is used for cooling blood and stopping bleeding to treat diseases of urinary systems such as pyelonephritis, chronic renal failure, hematuria and the like, 12-60 g of Chinese medicinal composition can be used; 9-30 g of the Chinese medicinal composition is commonly used for cooling blood and stopping bleeding, clearing heat and detoxicating and treating respiratory diseases such as pulmonary tuberculosis, asthma and hemoptysis. According to the different diseases to be treated, sanguisorba officinalis has different compatibility medicines, such as fructus Sophorae, flos Sophorae, radix Scutellariae, rhizoma Imperatae, rhizoma Bletillae, etc. which are often used for clearing heat, cooling blood and stopping bleeding; for removing heat from blood and toxic materials, inducing diuresis and treating stranguria, it is often combined with raw pagodatree pod, oldenlandia and the like; for removing blood stasis and stopping bleeding, it is often combined with notoginseng and pollen typhae, etc.; for astringency and hemostasis, it is often combined with Huang Qi, dang Shen and Sheng Ma.
Sesame blend oil (10-50 parts of sesame oil, 5-10 parts of linseed oil, 5-10 parts of walnut oil, 1-5 parts of olive oil, 1-5 parts of perilla oil, 1-5 parts of corn oil, 1-5 parts of sea buckthorn oil, 1-5 parts of soybean oil, 1-5 parts of rapeseed oil, 1-5 parts of hemp oil and 1-5 parts of linseed oil) is used as a plasticizer, benzyl alcohol is used as a bacteriostatic agent, isopropyl palmitate is used as a skin softener, and camphor can be used as an aromatic.
Dyclonine hydrochloride is a novel local anesthetic which is absorbed through skin mucosa, reduces the sensibility of skin or mucosa by blocking the conduction of peripheral nerves, can block the conduction of stimulation caused by various nerve impulses, inhibits touch sense and pain sense, and has the effects of relieving pain, itching and sterilizing on the skin. Has the characteristics of quick response, lasting effect, strong penetrating power and small adverse drug reaction, is only used for external application, and is 1% solution for mucous membrane, no more than 10ml at a time, 0.5% emulsion for spraying, no more than 20ml at a time, and 1% ointment cream or 0.5% solution for skin. Overdosing of dyclonine hydrochloride can lead to elevated blood levels and excessive amounts can lead to symptoms of convulsions. Debilitating, elderly, acute and children should be dosed down according to their age, weight and physical condition.
Secondly, the benzalkonium chloride is important, and the benzalkonium chloride is a novel broad-spectrum bactericide, plays an antibacterial role through physical permeation, has the characteristics of good disinfection effect, small irritation, high safety, wide sterilization range and the like, and is widely used for preventing various infections clinically. In the absence of benzalkonium chloride, the patient's wound is highly likely to be infected.
Compared with the prior art, the invention has the following beneficial effects:
the sanguisorba officinalis liquid wound healing agent is added with some medicines for relieving pain and stopping bleeding, so that the healing of wounds is quickened under the action of the medicines and in a moist environment, and the pain of wounded patients is reduced.
Drawings
FIG. 1 is a graph showing the elongation of different amounts of nitrocellulose used in example 2.
FIG. 2 is a graph of tensile strength for different amounts of nitrocellulose used in example 2.
FIG. 3 shows MVTR values for different amounts of nitrocellulose as in example 2.
FIG. 4 is a graph showing the water loss rate for different amounts of nitrocellulose used in example 2.
Detailed Description
Example 1
The embodiment provides a liquid wound-promoting and healing agent of sanguisorba officinalis, which comprises the following components: 60g of nitrocellulose, 60g of sesame blend oil (sesame oil, 5g of linseed oil, 5g of walnut oil, 1g of olive oil, 1g of perilla oil, 1g of corn oil, 1g of sea buckthorn oil, 1g of soybean oil, 1g of rapeseed oil, 1g of hemp oil), 35g of benzyl alcohol, 20g of tocopherol acetate, 3g of camphor, 2g of benzalkonium chloride, 19.8g of isopropyl palmitate, 1.2g of sweet osmanthus oil, 5g of orange essential oil, 30g of sanguisorba extract (6 kg of sanguisorba raw material; water extraction and drying, (1) washing sanguisorba and soaking in water for 12 hours, (2) 10 times of water is boiled for 1 hour, (3) 5 times of water is boiled for 1 hour of crude drug, (4) dregs are discarded to obtain an extract, (5) spray drying), 10g of dyclonine hydrochloride, and the selected solvents are isopropanol 405g, ethyl acetate 225g and butyl acetate 182g, so as to obtain 1000g of liquid wound healing promoting agent, and the aluminum tube is filled in each tube (20 g). The liquid wound healing promoting agent prepared by uniformly stirring the raw materials has good spreadability, and can rapidly form a film on the surface of skin to cover a wound. The film prepared by the method has good mechanical properties.
Example 2
The nitrocellulose is used as a membrane material, so that the waterproof and antibacterial properties are excellent, 4%, 6% and 8% of nitrocellulose are respectively used for preparing the liquid wound dressing, and the prepared film is evaluated. When 4% nitrocellulose is used for preparing the liquid wound dressing, other components are as follows: 32g of sesame blend oil, 18g of benzyl alcohol, 2.8g of tocopheryl acetate, 2.5g of camphor, 2.5g of benzalkonium chloride, 18.9g of isopropyl palmitate, 1.8g of osmanthus fragrans oil, 5.5g of orange essential oil, 35g of garden burnet extract, 9g of dyclonine hydrochloride, 420g of isopropanol, 222g of ethyl acetate and 190g of butyl acetate. When the liquid wound dressing is prepared by adopting 6% nitrocellulose, the other components are as follows: 35g of sesame blend oil, 20g of benzyl alcohol, 2g of tocopheryl acetate, 3g of camphor, 2g of benzalkonium chloride, 19.8g of isopropyl palmitate, 1.2g of osmanthus fragrans oil, 5g of orange essential oil, 30g of sanguisorba extract, 10g of dyclonine hydrochloride, and 405g of isopropanol, 225g of ethyl acetate and 182g of butyl acetate as solvents. When 8% nitrocellulose is used for preparing the liquid wound dressing, other components are as follows: 38g of sesame blend oil, 18g of benzyl alcohol, 2.5g of tocopheryl acetate, 3.5g of camphor, 1.5g of benzalkonium chloride, 20g of isopropyl palmitate, 1.5g of osmanthus fragrans oil, 4.5g of orange essential oil, 25g of sanguisorba extract, 10.5g of dyclonine hydrochloride, 390g of isopropanol, 230g of ethyl acetate and 175g of butyl acetate. From fig. 1 and fig. 2, it can be seen that when the amount of nitrocellulose is 4% and 6%, the breakpoint elongation percentage is 170% or more, and the film is considered to have better toughness and better comfort on the wound surface, and when the amount of nitrocellulose is 8%, the breakpoint elongation percentage is lower and less than 150%;at a nitrocellulose level of 4%, the film produced is too thin, resulting in poor tensile strength, less than 2.0MPa. As can be seen from FIG. 3, the MVTR value is between 0.3 and 0.6 mg/(cm) 2 H) decrease with increasing nitrocellulose amount, but all have a certain air permeability; as can be seen from fig. 4, the water loss rate of each of the three different gradient nitrocellulose was 2.5% or less in 24 hours, and it was considered that the water repellency was good. In conclusion, the amount of the nitrocellulose adopted in the present time is 6 percent.
Testing of the elongation and tensile strength of nitrocellulose using a tensile tester and using the formula: tensile strength = f/s, percent break elongation = maximum tensile distance/initial film length x 100%, adding distilled water to a penicillin bottle, covering and sealing with a film to distance the water level from the filmmm, in a desiccator, the weight difference after 24 hours was recorded, and the MVTR value and water loss rate of the nitrocellulose were calculated from the formulas: water loss rate = (initial penicillin bottle weight-24 h post penicillin bottle weight)/penicillin bottle water weight.
Example 3
20 rabbits are selected, and the weight of the rabbits is 2.0-2.3kg. The method is divided into five groups randomly, namely a blank control group, a positive control group, a garden burnet high-concentration administration group, a garden burnet medium-concentration administration group and a garden burnet low-concentration administration group, wherein 4 groups are respectively male and female halves. Removing hair around the vein of the right ear edge of an experimental animal, lightly flicking the bleeding mould of the ear after disinfection, cutting off the vein of the ear edge at the position 7-8cm from the tip of the ear of the right ear, applying different groups of test objects to wounds, applying medicinal starch gauze to a blank control group, applying Yunnan white drug powder gauze to a positive control group, and respectively applying gauze containing water extracts of sanguisorba officinalis with different concentrations according to the crude drug amount to a high-medium-low concentration administration group of sanguisorba officinalis. The above operation method is adopted for the auricle artery of the left ear of the experimental animal.
The timing was stopped from the start of bleeding to the absence of bleeding from the wound being made, giving rise to bleeding time.
Blank (medicinal starch);
positive control (yunnan white drug);
high concentration 2g/mL of water extract based on crude drug;
the dosage of the water extract with the medium concentration is 1g/mL according to the crude drug amount;
the low concentration dosage is 0.5g/mL of the water extract based on crude drug.
Influence of Sanguisorbae on the bleeding time of middle artery of rabbit ear
| Group of | Number of animal ears | Bleeding time(s) |
| Blank control group | 8 | 381.64±70.91 |
| Positive control group | 8 | 179.82±72.13 |
| High-concentration administration group of sanguisorba officinalis | 8 | 131.34±74.68 |
| Ulmus pumila medium concentration dosing group | 8 | 193.96±81.43 |
| Low concentration administration group of garden burnet | 8 | 297.62±79.82 |
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the design spirit of the present invention.
Claims (6)
1. The liquid wound-promoting and healing agent for the garden burnet is characterized by comprising the following components in parts by weight: 40-80 parts of nitrocellulose, 30-40 parts of sesame blend oil, 15-25 parts of benzyl alcohol, 1-3 parts of tocopheryl acetate, 2-4 parts of camphor, 1-3 parts of benzalkonium chloride, 18-21 parts of isopropyl palmitate, 1-2 parts of osmanthus fragrans oil, 4-6 parts of orange essential oil, 20-40 parts of sanguisorba extract, 8-12 parts of dyclonine hydrochloride, 380-420 parts of isopropanol, 200-240 parts of ethyl acetate and 170-190 parts of butyl acetate.
2. The liquid wound-promoting and healing agent for sanguisorba officinalis of claim 1, which is composed of the following components in parts by weight: 60 parts of nitrocellulose, 35 parts of sesame blend oil, 20 parts of benzyl alcohol, 2 parts of tocopheryl acetate, 3 parts of camphor, 2 parts of benzalkonium chloride, 19.8 parts of isopropyl palmitate, 1.2 parts of osmanthus fragrans oil, 5 parts of orange essential oil, 30 parts of sanguisorba extract, 10 parts of dyclonine hydrochloride, 405 parts of isopropanol, 225 parts of ethyl acetate and 182 parts of butyl acetate.
3. The liquid wound-promoting and healing agent for sanguisorba officinalis of claim 1, which is composed of the following components in parts by weight: 80 parts of nitrocellulose, 38 parts of sesame blend oil, 18 parts of benzyl alcohol, 2.5 parts of tocopheryl acetate, 3.5 parts of camphor, 1.5 parts of benzalkonium chloride, 20 parts of isopropyl palmitate, 1.5 parts of osmanthus fragrans oil, 4.5 parts of orange essential oil, 25 parts of garden burnet extract, 10.5 parts of dyclonine hydrochloride, 390 parts of isopropanol, 230 parts of ethyl acetate and 175 parts of butyl acetate.
4. The liquid wound-promoting and healing agent for sanguisorba officinalis of claim 1, which is composed of the following components in parts by weight: 40 parts of nitrocellulose, 32 parts of sesame blend oil, 18 parts of benzyl alcohol, 2.8 parts of tocopheryl acetate, 2.5 parts of camphor, 2.5 parts of benzalkonium chloride, 18.9 parts of isopropyl palmitate, 1.8 parts of osmanthus fragrans oil, 5.5 parts of orange essential oil, 35 parts of garden burnet extract, 9 parts of dyclonine hydrochloride, 420 parts of isopropanol, 222 parts of ethyl acetate and 190 parts of butyl acetate.
5. The liquid wound healing agent of sanguisorba officinalis according to any one of claims 1 to 4, wherein the preparation method of the sanguisorba officinalis extract is as follows: 5500-6500 parts of garden burnet raw material; extracting and drying the raw medicinal liquid: (1) washing the sanguisorba officinalis and soaking the sanguisorba officinalis in water for 12 hours; (2) the sanguisorba officinalis is boiled for 1 hour by 10 times of water; (3) boiling the secondary sanguisorba officinalis with 5 times of water for 1 hour; (4) discarding residues to obtain an extract; (5) spray drying.
6. Use of the sanguisorba officinalis liquid wound healing agent according to any one of claims 1 to 4 for preparing a wound healing promoting medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310515553.XA CN116531433A (en) | 2023-05-09 | 2023-05-09 | Liquid wound healing agent of garden burnet and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310515553.XA CN116531433A (en) | 2023-05-09 | 2023-05-09 | Liquid wound healing agent of garden burnet and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116531433A true CN116531433A (en) | 2023-08-04 |
Family
ID=87450132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310515553.XA Pending CN116531433A (en) | 2023-05-09 | 2023-05-09 | Liquid wound healing agent of garden burnet and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116531433A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584721A (en) * | 2009-07-06 | 2009-11-25 | 江苏泰灵生物科技有限公司 | Chinese traditional medicine antibiotic hemostatic plaster |
| CN104971377A (en) * | 2015-06-23 | 2015-10-14 | 潘秀娟 | Liquid wound glue and preparation method |
| CN105688270A (en) * | 2016-01-07 | 2016-06-22 | 王清清 | Liquid band-aid and preparing method thereof |
-
2023
- 2023-05-09 CN CN202310515553.XA patent/CN116531433A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584721A (en) * | 2009-07-06 | 2009-11-25 | 江苏泰灵生物科技有限公司 | Chinese traditional medicine antibiotic hemostatic plaster |
| CN104971377A (en) * | 2015-06-23 | 2015-10-14 | 潘秀娟 | Liquid wound glue and preparation method |
| CN105688270A (en) * | 2016-01-07 | 2016-06-22 | 王清清 | Liquid band-aid and preparing method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 张灵娜;王天宇;洪婉凤;陶春;宋洪涛;: "以硝化纤维为膜材的伤口敷料的制备及处方优化", 药学实践杂志, no. 04, pages 301 - 306 * |
| 王君;吴晖;胡博志;林熠;喻琳;郑宏宇;曾志军;: "液体创口贴用于皮肤损伤创面保护的临床研究", 海峡药学, no. 09, pages 143 - 145 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11571452B2 (en) | Method of treating a skin wound with a liquid-state topical pharmaceutical composition | |
| CN108186711A (en) | Promote the pharmaceutical composition of wound healing | |
| CN104288504B (en) | A kind of Chinese medicine ointment formulation for treating burn, scald and preparation method thereof | |
| CN103202903A (en) | Traditional Chinese medicine preparation for treating skin eczema | |
| CN101869636B (en) | Sinkiang arnebia oil cream | |
| CN103610841B (en) | A kind of method for the treatment of bamboo rat stomatitis | |
| CN103721138B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating rosacea | |
| CN105535822A (en) | Traditional Chinese medicine composition for treating haemorrhoids and preparation method thereof | |
| CN116531433A (en) | Liquid wound healing agent of garden burnet and application thereof | |
| CN103142727B (en) | Chinese herbal medicine composition for treating burning and scalding of human body | |
| CN102824563B (en) | Method for preparing Chinese medicinal lotion for treating closed fracture due to frequent micturition and urgent micturition | |
| CN106728069B (en) | Slough-removing and tissue regeneration-promoting paste for treating scalds and burns | |
| CN109045204A (en) | A kind of herb liquid and preparation method thereof for treating burn and scald | |
| CN115381875B (en) | Traditional Chinese medicine composition for external hemorrhoids and mixed hemorrhoids after operation, lotion and application | |
| CN115414415B (en) | A Chinese medicinal composition for treating skin injury and ulcer, and its preparation method | |
| CN112022933B (en) | Pharmaceutical composition for treating stomachache with syndrome of qi stagnation and blood stasis | |
| CN107951930A (en) | It is a kind of to be used to treat spray of allergic rhinitis and preparation method thereof | |
| CN106421641A (en) | Traditional Chinese medicine composition and preparation for treating anorectal diseases | |
| CN105265786A (en) | Compound feed for cows and preparation method thereof | |
| CN105535209A (en) | External washing traditional Chinese medicine composition for treating haemorrhoids | |
| CN103933230A (en) | Traditional Chinese medicine ointment for treating external hemorrhoids | |
| CN114099421A (en) | A topical Chinese medicinal preparation for treating scald and burn, and its preparation method | |
| CN114470091A (en) | Health-care plaster for treating heat cough | |
| CN108452048A (en) | A kind of burn medicine and preparation method thereof | |
| CN104257797A (en) | Traditional Chinese medicine oral decoction for treating skin allergy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |